Payment overview · 2025
General Payments
$334.44
20 reported records · 10 companies
Healthcare provider profile · identity verified
Eric West, MD
Allopathic & Osteopathic Physicians|Internal Medicine · OKLAHOMA CITY, OK · NPI 1255375226
Verified facts
What the public records show
CMS Open Payments records show Eric West, MD received $334.44 in general payments during 2025 across 20 reported records.
Lilly USA, LLC accounted for 23.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $77.18 | 23.1% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $67.41 | 20.2% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $53.13 | 15.9% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $37.68 | 11.3% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.47 | 5.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.30 | 5.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.75 | 5.0% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $15.71 | 4.7% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.41 | 4.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.40 | 4.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $334.44 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $77.18 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $77.18 | 5 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $67.41 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $67.41 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $51.06 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $19.68 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $19.27 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $18.83 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $18.47 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.30 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.30 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.75 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.75 | 1 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $16.35 | 1 | 2025 |
Source payment records
|
|||||
| TRUMENBA Normalized: trumenba |
Biological | PFIZER INC. | $16.35 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $15.41 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.40 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.40 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.18 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 62 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 75 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 167 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
42 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
53 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
62 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
108 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
75 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
75 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
142 | 33 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
167 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
134 | 31 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 899 | 268 |
| Amlodipine Besylate | Amlodipine Besylate | 448 | 129 |
| Levothyroxine Sodium | Levothyroxine Sodium | 436 | 92 |
| Pantoprazole Sodium | Pantoprazole Sodium | 421 | 104 |
| Lisinopril | Lisinopril | 343 | 80 |
| Losartan Potassium | Losartan Potassium | 329 | 105 |
| Omeprazole | Omeprazole | 328 | 72 |
| Gabapentin | Gabapentin | 295 | 87 |
| Escitalopram Oxalate | Escitalopram Oxalate | 249 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 248 | 74 |
| Potassium Chloride | Potassium Chloride | 247 | 60 |
| Tamsulosin Hcl | Tamsulosin Hcl | 231 | 53 |
| Tizanidine Hcl | Tizanidine Hcl | 214 | 54 |
| Metformin Hcl | Metformin Hcl | 205 | 40 |
| Furosemide | Furosemide | 187 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 180 | 39 |
| Risperidone | Risperidone | 180 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 178 | 56 |
| Ozempic | Semaglutide | 167 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 161 | 65 |
| Trazodone Hcl | Trazodone Hcl | 156 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 153 | 40 |
| Sertraline Hcl | Sertraline Hcl | 144 | 32 |
| Trulicity | Dulaglutide | 142 | 33 |
| Carvedilol | Carvedilol | 139 | 44 |
| Meloxicam | Meloxicam | 137 | 26 |
| Eliquis | Apixaban | 134 | 31 |
| Levetiracetam | Levetiracetam | 128 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 125 | 35 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 115 | 32 |
| Benztropine Mesylate | Benztropine Mesylate | 113 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 110 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 109 | 33 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 108 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 103 | 35 |
| Pregabalin | Pregabalin | 102 | 16 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 101 | 20 |
| Allopurinol | Allopurinol | 100 | 24 |
| Divalproex Sodium | Divalproex Sodium | 100 | suppressed |
| Glimepiride | Glimepiride | 99 | 29 |
| Alendronate Sodium | Alendronate Sodium | 97 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 95 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 95 | 29 |
| Famotidine | Famotidine | 91 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 89 | 24 |
| Divalproex Sodium Er | Divalproex Sodium | 88 | suppressed |
| Simvastatin | Simvastatin | 88 | 20 |
| Lactulose | Lactulose | 87 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 84 | 25 |
| Ibuprofen | Ibuprofen | 84 | 30 |
| Etodolac | Etodolac | 82 | 24 |
| Januvia | Sitagliptin Phosphate | 82 | 18 |
| Memantine Hcl | Memantine Hcl | 77 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 76 | 15 |
| Olanzapine | Olanzapine | 76 | suppressed |
| Jardiance | Empagliflozin | 75 | 19 |
| Mounjaro | Tirzepatide | 75 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 72 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 69 | 11 |
| Metformin Hcl Er | Metformin Hcl | 68 | 24 |
| Montelukast Sodium | Montelukast Sodium | 68 | 17 |
| Warfarin Sodium | Warfarin Sodium | 66 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 64 | 16 |
| Ondansetron Odt | Ondansetron | 63 | 20 |
| Atenolol | Atenolol | 62 | 14 |
| Farxiga | Dapagliflozin Propanediol | 62 | 14 |
| Topiramate | Topiramate | 59 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 56 | 13 |
| Donepezil Hcl | Donepezil Hcl | 55 | 19 |
| Azithromycin | Azithromycin | 54 | 44 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 54 | suppressed |
| Synthroid | Levothyroxine Sodium | 53 | 14 |
| Clozapine | Clozapine | 52 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 50 | 28 |
| Lamotrigine | Lamotrigine | 49 | suppressed |
| Aripiprazole | Aripiprazole | 48 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 47 | 16 |
| Carbamazepine | Carbamazepine | 46 | suppressed |
| Glipizide | Glipizide | 46 | 11 |
| Myrbetriq | Mirabegron | 46 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 45 | 38 |
| Ketoconazole | Ketoconazole | 45 | 12 |
| Oxcarbazepine | Oxcarbazepine | 44 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 43 | suppressed |
| Baclofen | Baclofen | 42 | suppressed |
| Linzess | Linaclotide | 42 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 42 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | 12 |
| Methylprednisolone | Methylprednisolone | 39 | 24 |
| Doxazosin Mesylate | Doxazosin Mesylate | 38 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 37 | 12 |
| Torsemide | Torsemide | 37 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 36 | 30 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | 11 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 35 | 33 |
| Ezetimibe | Ezetimibe | 35 | 14 |
| Invega Sustenna | Paliperidone Palmitate | 35 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 34 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Digoxin | Digoxin | 30 | suppressed |
| Prednisone | Prednisone | 29 | 15 |
| Spiriva Respimat | Tiotropium Bromide | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | 12 |
| Novolog Flexpen | Insulin Aspart | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Finasteride | Finasteride | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 26 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 26 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 25 | suppressed |
| Enulose | Lactulose | 25 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 25 | suppressed |
| Paliperidone Er | Paliperidone | 25 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 25 | suppressed |
| Clonazepam | Clonazepam | 24 | suppressed |
| Dutasteride | Dutasteride | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 22 | 13 |
| Atomoxetine Hcl | Atomoxetine Hcl | 21 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 21 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 20 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Pindolol | Pindolol | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 12 |
| Spiriva Handihaler | Tiotropium Bromide | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 18 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Vraylar | Cariprazine Hcl | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Bromocriptine Mesylate | Bromocriptine Mesylate | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Lacosamide | Lacosamide | 16 | suppressed |
| Latanoprost | Latanoprost | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Xifaxan | Rifaximin | 16 | suppressed |
| Clotrimazole | Clotrimazole | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Scopolamine | Scopolamine | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Nystop | Nystatin | 12 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Zafirlukast | Zafirlukast | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Norethindrone Acetate | Norethindrone Acetate | 11 | suppressed |
| Riluzole | Riluzole | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $334.44 · 20 records | Lilly USA, LLC | ABRYSVO, AIRSUPRA, AREXVY, BREZTRI, COMIRNATY, Cologuard Collection Kit, FARXIGA, GVOKE HYPOPEN, Kerendia, MOUNJARO, Ozempic, PENBRAYA, PREVNAR 20, QULIPTA, Rybelsus, SHINGRIX, TRUMENBA, The Cologuard Plus Collection Kit, UBRELVY, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error